Log In
BCIQ
Print this Print this
 

XMT-1522

  Manage Alerts
Collapse Summary General Information
Company Mersana Therapeutics Inc.
DescriptionAntibody-drug conjugate (ADC) targeting epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu)
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$40.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/03/2016

Undisclosed

$40.0M

Undisclosed

Get a free BioCentury trial today